Dantrolene Sodium

Neonatal

FORM Vial containing 20 mg powder for reconstitution

INDICATION For the treatment of malignant hyperthermia

DOSE RANGE

AGE	DOSE	FREQUENCY	ROUTE
Neonate to 6 months	Initially 2-3mg/kg, followed by 1mg/kg doses repeated if necessary to maximum cumulative dose of 10mg/kg	Bolus	Rapid I/V

MHAUS (Malignant Hyperthermia Association of the USA) recommendation: continue therapy with 1mg/kg/dose every 6 hours for at least 24 hours after control of symptoms

RECONSTITUTION Dissolve contents of vial with 59ml of bacteriostat free water for injection to give a 1mg in 3ml solution

DILUTION Not required

METHOD OF ADMINISTRATION Rapid intravenous injection. Lines must only be flushed with water for injection

Administer via a central line if possible.

COMPATIBILITY

Solution compatibility	Water for injection
Solution incompatibility	All intravenous infusions
IV Line compatibility	No information
IV Line incompatibility	No information

THIS LIST IS NOT EXHAUSTIVE PLEASE CONTACT PHARMACY FOR FURTHER INFORMATION ON COMPATIBILITY WITH ANY MEDICINES NOT INCLUDED

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION Because of the high pH of the intravenous formulation of Dantrium Intravenous and potential for tissue necrosis, care must be taken to prevent extravasation of the intravenous solution into the surrounding tissues.

When mannitol is used for the prevention or the treatment of renal complications of malignant hyperthermia, the 3000 mg of mannitol present as an excipient in each vial of intravenous dantrolene sodium (20 mg) should be taken into consideration when calculating total mannitol dose to be administered.

Administration of dantrolene may potentiate vecuronium-induced neuromuscular block

PH 9.5

West of Scotland NEONATAL Parenteral Drug Monographs

LICENSED STATUS Unlicensed use in children and neonates

LINKS BNF for Children: / Electronic Medicines Compendium

APPLICABLE POLICIES West of Scotland Neonatal Guidelines:

Consult local policy if applicable

Document Number:	002	Supersedes:	001
Prepared by:	WoS neo Pharm Group	Checked by	Marie L Currie
Date prepared	May 2016	Date updated	September 2019
Updated by	Marie Stewart	Review Date	September 2022

Administer reconstituted solutions immediately.
All vials, ampoules and infusion bags are for single use only unless otherwise stated.
Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications.
This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.